InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,577.98
(
0.09%
)
US TECH 100
19,874.10
(
-0.10%
)
Dow Jones
39,340.04
(
-0.01%
)
Brent Oil
84.61
(
-0.95%
)
Bitcoin
57,457.72
(
1.33%
)
Post# of 252528
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119993
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 74831

Sunday, 03/22/2009 12:47:19 AM

Sunday, March 22, 2009 12:47:19 AM

Post# of 252528
In the "12+12" arm of PROVE-3, the % with undetectable virus at 12 weeks (end of Telaprevir portion of treatment) was 75% (86/115), and the % with undetectable virus at 24 weeks (end of all treatment) was 70% (80/115 or 81/115). (These numbers were reported in June 2008: #msg-29896176). Thus, 5 or 6 of the 86 patients in question had a viral breakthrough while on the SoC portion of the regimen.

Corresponding data for the "24+24" arm have not been disclosed.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up